Commentary on Cohen et al.: Role of Clinical Factors in Precision Medicine Test to Predict Nonresponse to TNFi Therapies in Rheumatoid Arthritis

Cohen S, Wells AF, Curtis JR, et al. A molecular signature response classifier to predict inadequate response to tumor necrosis factor-alpha inhibitors: the NETWORK-004 prospective observational study. Rheumatol Ther. 2021;8:1159–76.

Article  PubMed  PubMed Central  Google Scholar 

Daien CI, Morel J. Predictive factors of response to biological disease modifying antirheumatic drugs: towards personalized medicine. Mediators Inflamm. 2014;2014: 386148.

Article  PubMed  PubMed Central  Google Scholar 

Law-Wan J, Sparfel MA, Derolez S, et al. Predictors of response to TNF inhibitors in rheumatoid arthritis: an individual patient data pooled analysis of randomised controlled trials. RMD Open. 2021;7: e001882.

Article  PubMed  PubMed Central  Google Scholar 

Romano C, Esposito S, Ferrara R, et al. Tailoring biologic therapy for real-world rheumatoid arthritis patients. Expert Opin Biol Ther. 2021;21:661–74.

Article  PubMed  Google Scholar 

Wijbrandts CA, Tak PP. Prediction of response to targeted treatment in rheumatoid arthritis. Mayo Clin Proc. 2017;92:1129–43.

Article  CAS  PubMed  Google Scholar 

Madrid-Paredes A, Martin J, Marquez A. Omic approaches and treatment response in rheumatoid arthritis. Pharmaceutics. 2022;8:14.

Google Scholar 

Baker JF, Reed G, Poudel DR, et al. Obesity and response to advanced therapies in rheumatoid arthritis. Arthritis Care Res (Hoboken). 2022;74:1909–16.

Article  CAS  PubMed  Google Scholar 

Abuhelwa AY, Hopkins AM, Sorich MJ, et al. Association between obesity and remission in rheumatoid arthritis patients treated with disease-modifying anti-rheumatic drugs. Sci Rep. 2020;29(10):18634.

Article  Google Scholar 

Lupoli R, Pizzicato P, Scalera A, et al. Impact of body weight on the achievement of minimal disease activity in patients with rheumatic diseases: a systematic review and meta-analysis. Arthritis Res Ther. 2016;13(18):297.

Article  Google Scholar 

Jawaheer D, Olsen J, Hetland ML. Sex differences in response to anti-tumor necrosis factor therapy in early and established rheumatoid arthritis—results from the DANBIO registry. J Rheumatol. 2012;39:46–53.

Article  PubMed  Google Scholar 

Hyrich KL, Watson KD, Silman AJ, et al. Predictors of response to anti-TNF-alpha therapy among patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register. Rheumatology (Oxford). 2006;45:1558–65.

Article  CAS  PubMed  Google Scholar 

Burmester GR, Ferraccioli G, Flipo RM, et al. Clinical remission and/or minimal disease activity in patients receiving adalimumab treatment in a multinational, open-label, twelve-week study. Arthritis Rheum. 2008;15(59):32–41.

Article  Google Scholar 

Kleinert S, Tony HP, Krause A, et al. Impact of patient and disease characteristics on therapeutic success during adalimumab treatment of patients with rheumatoid arthritis: data from a German noninterventional observational study. Rheumatol Int. 2012;32:2759–67.

Article  CAS  PubMed  Google Scholar 

Lewis MJ, Barnes MR, Blighe K, et al. Molecular portraits of early rheumatoid arthritis identify clinical and treatment response phenotypes. Cell Rep. 2019;28:2455-2470 e5.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Aggarwal R, Liao K, Nair R, et al. Anti-citrullinated peptide antibody assays and their role in the diagnosis of rheumatoid arthritis. Arthritis Rheum. 2009;15(61):1472–83.

Article  Google Scholar 

Sokolove J, Schiff M, Fleischmann R, et al. Impact of baseline anti-cyclic citrullinated peptide-2 antibody concentration on efficacy outcomes following treatment with subcutaneous abatacept or adalimumab: 2-year results from the AMPLE trial. Ann Rheum Dis. 2016;75:709–14.

Article  CAS  PubMed  Google Scholar 

Vasilopoulos Y, Bagiatis V, Stamatopoulou D, et al. Association of anti-CCP positivity and carriage of TNFRII susceptibility variant with anti-TNF-alpha response in rheumatoid arthritis. Clin Exp Rheumatol. 2011;29:701–4.

CAS  PubMed  Google Scholar 

Tanaka Y, Takeuchi T, Inoue E, et al. Retrospective clinical study on the notable efficacy and related factors of infliximab therapy in a rheumatoid arthritis management group in Japan: one-year clinical outcomes (RECONFIRM-2). Mod Rheumatol. 2008;18:146–52.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Potter C, Hyrich KL, Tracey A, et al. Association of rheumatoid factor and anti-cyclic citrullinated peptide positivity, but not carriage of shared epitope or PTPN22 susceptibility variants, with anti-tumour necrosis factor response in rheumatoid arthritis. Ann Rheum Dis. 2009;68:69–74.

Article  CAS  PubMed  Google Scholar 

Mancarella L, Bobbio-Pallavicini F, Ceccarelli F, et al. Good clinical response, remission, and predictors of remission in rheumatoid arthritis patients treated with tumor necrosis factor-alpha blockers: the GISEA study. J Rheumatol. 2007;34:1670–3.

CAS  PubMed  Google Scholar 

Klaasen R, Cantaert T, Wijbrandts CA, et al. The value of rheumatoid factor and anti-citrullinated protein antibodies as predictors of response to infliximab in rheumatoid arthritis: an exploratory study. Rheumatology (Oxford). 2011;50:1487–93.

Article  CAS  PubMed  Google Scholar 

Cuchacovich M, Catalan D, Wainstein E, et al. Basal anti-cyclic citrullinated peptide (anti-CCP) antibody levels and a decrease in anti-CCP titres are associated with clinical response to adalimumab in rheumatoid arthritis. Clin Exp Rheumatol. 2008;26:1067–73.

CAS  PubMed  Google Scholar 

Canhao H, Rodrigues AM, Mourao AF, et al. Comparative effectiveness and predictors of response to tumour necrosis factor inhibitor therapies in rheumatoid arthritis. Rheumatology (Oxford). 2012;51:2020–6.

Article  CAS  PubMed  Google Scholar 

Braun-Moscovici Y, Markovits D, Zinder O, et al. Anti-cyclic citrullinated protein antibodies as a predictor of response to anti-tumor necrosis factor-alpha therapy in patients with rheumatoid arthritis. J Rheumatol. 2006;33:497–500.

CAS  PubMed  Google Scholar 

Soto L, Sabugo F, Catalan D, et al. The presence of anti-citrullinated protein antibodies (ACPA) does not affect the clinical response to adalimumab in a group of RA patients with the tumor necrosis factor (TNF) alpha-308 G/G promoter polymorphism. Clin Rheumatol. 2011;30:391–5.

Article  PubMed  Google Scholar 

Lequerre T, Jouen F, Brazier M, et al. Autoantibodies, metalloproteinases and bone markers in rheumatoid arthritis patients are unable to predict their responses to infliximab. Rheumatology (Oxford). 2007;46:446–53.

Article  CAS  PubMed  Google Scholar 

Bobbio-Pallavicini F, Caporali R, Alpini C, et al. High IgA rheumatoid factor levels are associated with poor clinical response to tumour necrosis factor alpha inhibitors in rheumatoid arthritis. Ann Rheum Dis. 2007;66:302–7.

Article  CAS  PubMed  Google Scholar 

Bruns A, Nicaise-Roland P, Hayem G, et al. Prospective cohort study of effects of infliximab on rheumatoid factor, anti-cyclic citrullinated peptide antibodies and antinuclear antibodies in patients with long-standing rheumatoid arthritis. Joint Bone Spine. 2009;76:248–53.

Article  CAS  PubMed  Google Scholar 

Saevarsdottir S, Wedren S, Seddighzadeh M, et al. Patients with early rheumatoid arthritis who smoke are less likely to respond to treatment with methotrexate and tumor necrosis factor inhibitors: observations from the epidemiological investigation of rheumatoid arthritis and the Swedish rheumatology register cohorts. Arthritis Rheum. 2011;63:26–36.

Article  CAS  PubMed  Google Scholar 

Soderlin MK, Petersson IF, Geborek P. The effect of smoking on response and drug survival in rheumatoid arthritis patients treated with their first anti-TNF drug. Scand J Rheumatol. 2012;41:1–9.

Article  CAS  PubMed  Google Scholar 

Mattey DL, Brownfield ANN, Dawes PT. Relationship between pack-year history of smoking and response to tumor necrosis factor antagonists in patients with rheumatoid arthritis. J Rheumatol. 2009;36:1180–7.

Article  PubMed  Google Scholar 

Abhishek A, Butt S, Gadsby K, et al. Anti-TNF-alpha agents are less effective for the treatment of rheumatoid arthritis in current smokers. J Clin Rheumatol. 2010;16:15–8.

Article  CAS  PubMed  Google Scholar 

Karaahmet OZ, Bal A, Dulgeroglu D, et al. Effect of exposure to tobacco smoke on response to anti-tumor necrosis factor-alpha treatment in patients with rheumatoid arthritis. Iran J Public Health. 2016;45:396–8.

PubMed  PubMed Central  Google Scholar 

Challa DNV, Crowson CS, Davis JM 3rd. The patient global assessment of disease activity in rheumatoid arthritis: identification of underlying latent factors. Rheumatol Ther. 2017;4:201–8.

Article  PubMed  PubMed Central  Google Scholar 

Meehan RT, Amigues IA, Knight V. Precision medicine for rheumatoid arthritis: the right drug for the right patient-companion diagnostics. Diagnostics (Basel). 2021;29:11.

Google Scholar 

Abdelhafiz D, Baker T, Glascow DA, et al. Biomarkers for the diagnosis and treatment of rheumatoid arthritis—a systematic review. Postgrad Med. 2022;16:1–10.

Article  Google Scholar 

Santos-Moreno P, Sanchez G, Castro C. Rheumatoid factor as predictor of response to treatment with anti-TNF alpha drugs in patients with rheumatoid arthritis: results of a cohort study. Medicine (Baltimore). 2019;98: e14181.

Article  CAS  PubMed  Google Scholar 

Michelsen B, Berget KT, Loge JH, et al. Sex difference in disease burden of inflammatory arthritis patients treated with tumor necrosis factor inhibitors as part of standard care. PLoS ONE. 2022;17: e0266816.

Article  CAS  PubMed  PubMed Central 

留言 (0)

沒有登入
gif